Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Genitourinary 1Dermatologic 1

Conditions

Prostatic Neoplasms 3Melanoma 3Neoplasms 2Lymphoma, Non-Hodgkin 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Neoplasm Metastasis 1Lymphoma 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Rituximab 205Cyclophosphamide 178Peripheral Blood Stem Cell Transplantation 93Etoposide 91fludarabine phosphate 86Filgrastim 81Melphalan 62Vincristine 60Mycophenolic Acid 58Busulfan 58Whole-Body Irradiation 57Cytarabine 51Radiotherapy 49Doxorubicin 49Cyclosporine 49Tacrolimus 48Granulocyte Colony-Stimulating Factor 48Prednisone 46fludarabine 45Bendamustine Hydrochloride 45Methotrexate 44Carmustine 36Antilymphocyte Serum 34Dexamethasone 32Bortezomib 29Gemcitabine 27ibritumomab tiuxetan 25Methylprednisolone 23sargramostim 22Stem Cell Transplantation 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, Non-Hodgkin × sepantronium × Clear all
NCT01007292 2015-10-19

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

Astellas Pharma Inc

Phase 2 Completed
43 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT00818480 2015-09-04

An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155

Astellas Pharma Inc

Phase 2 Completed
10 enrolled
DermatologicGenitourinaryLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡